Orchid Pharma shares closed 11.10 per cent up at Rs 43.05 after the company received an Establishment inspection report (EIR) from the US health regulator based on the successful inspection closure for the API manufacturing f
According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acquire the portfolio consisting of 14 established prescription brands from Novartis for a cash consideration of $293
Acquires 14 prescription brands Sun Pharma has acquired 14 established prescription brands from Novartis in Japan. According to the agreements entered into between the parties, a wholly-owned subsidiary of Sun Pharma will acq
Sun Pharmaceutical shares gained over 2 per cent on Wednesday after the company and its subsidiaries launched Imatinib Mesylate Tablets (therapeutic equivalent to Gleevec for indications approved by the FDA) in US market.
The company has received an order under the Competition Act, 2002, from the Competition Commission of India (CCI) approving the proposed transaction, Sun Pharmaceutical Industries said in a regulatory filing.
Factory ceilings which leaked and failure to follow written procedures designed to prevent microbiological contamination of drugs are some of the major norm violations found by the USFDA at Sun Pharma's Halol plant.